ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

Phase 1/2 Not yet recruiting 41 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, multicenter, phase II study designed to evaluate the efficacy and safety of MRG003, an anti-EGFR antibody-drug conjugate, in combination with QL1706, a PD-1/CTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based therapy.

Timeline

Start: 2026-04-10
Primary completion: 2028-03-31
Completion: 2030-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Becotatug Vedotin	Monoclonal antibody	2 mg/kg	Intravenous
Subject	QL1706	Monoclonal antibody	5 mg/kg	Intravenous

Indications

No indication recorded.